Human epidermal growth factor receptor 2 (HER2) is a member of the family of transmembrane receptor tyrosine kinases and is overexpressed in 20%-25% of women with breast cancer.
observed in clinical practice. AF is a major risk factor for thromboembolism and ischemic stroke, significantly increasing morbidity and mortality. 5 However, given the low number of AF cases reported in clinical trials, the risk attributable to trastuzumab use is less certain.
Therefore, the aims of this systematic review and meta-analysis are to determine the incidence of AF in clinical trials of assessing trastuzumab use and determine the various risk factors for AF development in patients receiving this drug.
| ME THODS
This meta-analysis of observational studies in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology statement.
| Search strategy and inclusion criteria
We systematically performed a literature search of the following database (PubMed and EMBASE) in September 2017, with combination of the terms: "trastuzumab," "Herceptin," "T-mab," and "atrial fibrillation." Reviewers also manually searched the existing reviews on trastuzumab effectiveness and checked the citations of all publications identified by the above search. If multiple articles were derived from the same cohort and involved the same population, we included only the most completed data for our primary analysis.
The inclusion criteria were (a) publications in English language; 
| Study selection
Two independent reviewers (M.Y. and G.T.) screened the titles and abstracts of the studies for eligibility. Potential studies were retrieved using the relevant inclusion criteria mentioned in the preceding. Articles identified after title and abstract screening were obtained in full text. Any cases of disagreements or uncertainty between the two reviewers were resolved through discussion or consultation with a third reviewer (T.L.).
| Data extraction and quality assessment
The same two reviewers independently extracted data from included studies. The following data were extracted from the eligible manuscripts: first author of the study, year of publication, study design, disease, treatments, participant age and sex, follow-up duration, dose of trastuzumab treatment, weeks with one cycle, the number of sample size, and the number of AF in T recipients. And assessed their methodological quality were used by the Newcastle-Ottawa Scale (NOS) items, 6 which with total score of nine stars, to evaluate the quality of observational studies. We defined the observational studies with NOS score ≥7 stars as high quality and NOS score <7 stars as low quality.
| Statistical analysis
All data analysis was performed using R software (i386, version 3.3.2).
The endpoint assessed was the incidence of AF. Crude study-specific AF rates were calculated by dividing the number of incident AF cases by the total number of patients which had received trastuzumab. AF rates were then pooled using the "metaprop" command in R, which computes the pooled estimates after the logit transformation to stabilize the variance. 
| RE SULTS
A flow diagram of the data search and study selection is summarized in Figure 1 . A total of 152 records were in the PubMed ; case reports (n = 1) 8 ; investigated trastuzumab combined with pertuzumab (n = 2) 9,10 ; duplicate population with another study (n = 1) 11 ; contained incomplete information (n = 1) 12 ; and mainly reported the therapeutic effects of trastuzumab (n = 1). 13 Therefore, 15 studies were included in this meta-analysis with the characteristics of the included studies shown in Table 1 . Five [14] [15] [16] [17] [18] were phase II, single-arm trials; three [19] [20] [21] were phase III trials; five [22] [23] [24] [25] [26] were prospective cohort studies;
and two 27, 28 were retrospective cohort studies. All of these studies conducted on breast cancer. The dose of trastuzumab ranged from 2 to 8 mg/kg, with 1-3 weeks between trastuzumab cycles.
The characteristics of the included patient populations are presented in Table 2 . The cohort included 8124 patients receiving trastuzumab treatment. Of these, 37 reported AF, giving rise to an incidence of 1.22% (95% confidence interval [CI]: 0.56%-2.68%).
Heterogeneity among studies was significant (I 2 = 79%, P < 0.01; The results from subgroup analyses are shown in Table 1 . Three [16] [17] [18] studies reported the incidence of AF using ado-trastuzumab Emtansine (T-DM1), which is an antibody-drug conjugate combining trastuzumab, with the maytansinoid DM1, a potent microtubule-disrupting agent. The incidence of AF was 0.95% (95% CI:
0.36%-2.52%) in patients with breast cancer with T-DM1, and no significant heterogeneity was found (I 2 = 0%, P = 0.78). Pooling data from twelve 14, 15, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] studies that reported outcomes of trastuzumab use alone demonstrated the incidence of AF of 1.32% (95% CI: 0.52%-3.34%), but significant heterogeneity among studies remained (I 2 = 83%, P < 0.01). The pooled estimates showed that incidence of AF was 1.72% (95% CI: 0.75%-3.88%) in patients with previous anthracyclines exposure and 1.03% (95% CI: 0.30%-3.51%) in patients without previous anthracyclines exposure. There was significant heterogeneity among studies (I 2 = 52%, P = 0.05; I 2 = 83%, P < 0.01, respectively).
Finally, six [14] [15] [16] 18, 24, 25 studies reported the adverse events of AF with exposure to radiotherapy (RT). Pooling data from these studies
showed that the incidence of AF was 1.26% (95% CI: 0.68%-2.33%).
No significant heterogeneity was reported (I 2 = 0%, P = 0.99).
Pooling data from nine 17, [19] [20] [21] [22] [23] [26] [27] [28] studies that reported outcomes of RT nonexposure demonstrated incidence of AF was 1.21% (95% CI:
0.35%-4.14%). There was significant heterogeneity among studies (I 2 = 88%, P < 0.01). 
| D ISCUSS I ON
The main findings of this systematic review and meta-analysis are that (a) the incidence of AF in breast cancer patients receiving trastuzumab therapy is just above 1% and (b) this incidence was not significantly different due to the type of trastuzumab (whether linked to DM1) and regimen (alone or combination with other anti-neoplastic agents or radiotherapy, or anthracyclines).
Atrial fibrillation is a known comorbidity that occurs with increasing frequency in cancer patients, especially in patients who undergoing surgery or chemotherapy. This represents an important aspect of cancer management, given the significantly increased risk of thromboembolism. 29 Both cancer progression and cancer therapy can increase the risk of AF. [29] [30] [31] AF is a poor prognostic factor during cancer therapy and leads to worsened outcomes. 32 The pathophysiological mechanism of cancer therapy-provoked AF is complicated, including myocardial damage due to inflammation and increased oxidative stress. [33] [34] [35] Higher levels of reactive oxygen species can cause ion channel dysfunction and remodeling, leading to conduction and/or repolarization abnormalities that predispose to arrhythmogenesis. 36 Trastuzumab is a monoclonal antibody used as a targeted therapy for HER2-positive breast cancer. It is generally effective in slowing cancer progression, and its use has been associated with lower rates of adverse events. Previous studies have also evaluated the relationship between trastuzumab use and adverse cardiovascular events.
For example, Wang et al 26 found that patients with early discontinuation of trastuzumab were more likely to suffer from heart failure, cardiomyopathy, AF, and other cardiovascular events than women who completed trastuzumab. The incidence of AF in those with early discontinuation of T was 5.4% vs <3.2% (P = 0.006). Furthermore, Chen et al 23 demonstrated that early termination of trastuzumab was significantly associated with AF (8.2% vs 2.1%, P = 0.02). It is possible that high prevalence of AF among older patients, these patients may be more symptomatic after developing AF compared with younger patients, and thus more likely to discontinue trastuzumab.
However, its cardiac toxicity profile cannot be ignored. Thus, safety studies in chick embryos reported that high dose of trastuzumab at 15 mg/egg resulted in AF development. 37 Moreover, trastuzumab significantly disrupted the expression of myocardial genes essential for DNA repair and mitochondrial function in mouse models. Thus, trastuzumab-induced cardiotoxicity may be related to higher levels of oxidative stress and cellular apoptosis. 38 Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab stably linked to the microtubule inhibitor RT, radiation therapy; T, trastuzumab; T-DM1, trastuzumabemtansine.
TA B L E 1 Characteristics of the studies included in the meta-analysis
DM1. 39 T-DM1 delivers DM1 directly to HER2 overexpressing tumor cells, depressing microtubule function, and inducing cell death. 40 Like trastuzumab, T-DM1 inhibits HER2 the signaling pathway, prevents HER2 shedding, and leads to antibody dependent cellular cytotoxicity. 41 Given the efficacy and good safety profile of T-DM1, there is increasing interest in using T-DM1 as a first-line agent.
Further studies are needed to confirm whether this is better than trastuzumab alone. Our findings suggest that AF incidence in T-DM1
was comparable to that of using trastuzumab alone.
Concurrent chemotherapy is a valuable method for adjuvant treatment of breast cancer. However, this is accompanied by significant cardiotoxicity, mostly when patients previously exposure to anthracyclines. 42, 43 For example, 3.9% developed severe symptomatic heart failure and up to 34% showed echocardiographic evidence of cardiac dysfunction when they were pretreated with anthracyclines. In our analysis, AF incidence in the prior exposure group was not significantly different from the incidence in patients without prior anthracycline use.
In early breast cancer, even after mastectomy, an appreciable risk of local recurrence of the tumor is still present, for which adjuvant radiotherapy has been shown to improve the OS. 44, 45 However, there have been suggestions that the combination of anticancer therapies can magnify cardiac toxicity, particularly after radiotherapy combined with chemotherapy. 46 Preclinical studies concerned that the potential radio-sensitizing properties of trastuzumab both in vivo and in vitro. 47 Our analysis also demonstrated that patients who concurrently received trastuzumab and radiotherapy had similar incidence of AF than those receiving trastuzumab without radiotherapy.
| Study limitations
Several potential limitations of this meta-analysis should be noted.
First, significant heterogeneity was found. Most of the included studies were phase II single-arm trials and cohort studies, and no control group was established. Second, AF was evaluated at baseline, at the end of anthracyclines treatment, after cycles of trastuzumab, as well as before and after the start of a new treatment. However, it was not possible to exclude the toxic effects of other antineoplastic drugs.
Third, the misclassification bias may occur because AF screening was not sufficiently intensive to detect paroxysmal AF. Forth, the level of baseline LVEF may one of the important factors associated with AF development but this parameter was only reported in two studies.
Further studies are needed to determine possible confounding from heart failure, which is a known risk factor for AF. Finally, this analysis was not sufficiently strong to provide the basis for any treatment recommendations or changes in practice. These need to be formally assessed in larger prospective real-world studies and clinical trials.
| CON CLUS IONS
This meta-analysis summarized and presented that the AF incidence in breast cancer patients using trastuzumab was more than 1%. Further studies and longer follow-up are warranted to confirm these results.
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